Geron：困境持续，机遇仍在积累（纳斯达克：GERN）
· seekingalpha.com
Geron于2024年6月获得FDA对RYTELO的批准，该药针对较低风险骨髓增生异常综合征。阅读本文，了解为何GERN股票具有吸引力，值得买入。
This is my latest in a long series of Geron ( GERN ) articles dating back to 04/2017. In the early days, investors were on tenterhooks to see whether Johnson & ...